Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

This page shows the publications co-authored by David Avigan and Dina Stroopinsky.
Connection Strength

5.240
  1. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 05 01; 106(5):1330-1342.
    View in: PubMed
    Score: 0.994
  2. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J Cell Mol Med. 2018 May 15.
    View in: PubMed
    Score: 0.810
  3. MUC1 in hematological malignancies. Leuk Lymphoma. 2016 11; 57(11):2489-98.
    View in: PubMed
    Score: 0.711
  4. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79.
    View in: PubMed
    Score: 0.580
  5. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. Br J Haematol. 2019 05; 185(4):679-690.
    View in: PubMed
    Score: 0.214
  6. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma. J Immunother. 2017 Nov/Dec; 40(9):315-322.
    View in: PubMed
    Score: 0.195
  7. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. . 2017 10; 16(10):2304-2314.
    View in: PubMed
    Score: 0.191
  8. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017 12; 31(12):2780-2790.
    View in: PubMed
    Score: 0.189
  9. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801.
    View in: PubMed
    Score: 0.185
  10. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
    View in: PubMed
    Score: 0.185
  11. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.183
  12. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Jul 16; 126(3):354-62.
    View in: PubMed
    Score: 0.165
  13. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
    View in: PubMed
    Score: 0.135
  14. Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity. Eur J Immunol. 2009 Oct; 39(10):2703-15.
    View in: PubMed
    Score: 0.111
  15. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin Cancer Res. 2021 Feb 15; 27(4):1139-1149.
    View in: PubMed
    Score: 0.060
  16. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res. 2019 06; 29(6):446-459.
    View in: PubMed
    Score: 0.054
  17. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. 2019 01; 33(1):132-147.
    View in: PubMed
    Score: 0.051
  18. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845.
    View in: PubMed
    Score: 0.050
  19. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.049
  20. Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets. Biomicrofluidics. 2016 Sep; 10(5):054115.
    View in: PubMed
    Score: 0.045
  21. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987.
    View in: PubMed
    Score: 0.044
  22. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.